Profectus immunizes first patient in Ph1 HIV vax trial

Baltimore-based Profectus Biosciences has inoculated its first patient in a Phase I trial of its multi-antigen DNA HIV vaccine. The study will monitor 60 HIV patients who are on stable anti-retroviral therapy, and dose them with the MAG-pDNA vaccine and varying levels of GENEVAX interleukin-12 adjuvant, MAG-pDNA vaccine alone or a placebo. The study is being sponsored by the National Institutes of Allergy and Infectious Diseases.

"This study will provide important information as to the most adjuvant active dose of GENEVAX IL-12, and it will do so in combination with the Profectus therapeutic vaccine in HIV infected subjects," said Dr. John Eldridge, Profectus' Chief Science Officer, in a release. "Improving the length and quality of life for those living with HIV infection is a goal we have been working toward for many years."

The study uses Ichor Medical System's TriGrid electroportation system to deliver GENEVAX. According to pre-clinical results, the MAG-pDNA vaccine in conjunction with GENEVAX creates a strong cell-mediated immune response during anti-retroviral therapy.

- see the Profectus release

Special Report: Successes, failures mark 30 years of HIV/AIDS research

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.